Well, CTIC picked up a not so good JAK2/FLT3 drug ONXX discarded. Surprised BioWorld had a lengthy article on it today. I suppose they at least discussed with FDA/EMA on ph3 trial design for MF. It doesn't mean they can carry out the plan as planned though smile.
Somehow I can already smell the failure in this trial.
The trial does not allow JAK inhibitors on the comparator arm. By the time enrollment is getting up to speed, patients are going to want to be on such and not willing to enroll in CTIC's trial. With enrollment drying up, they just call an early halt (possibly timed after seeing data).
Wouldn't be a first for CTIC, not even a second.
Market Data 
Markets 
AI
